Multiple myeloma Clinical Trials in New York, NY
As of June 2026, 52 paid clinical trials are recruiting for Multiple myeloma in New York, New York. Recruiting Multiple myeloma studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Related specialties in New York
Filter results
52 clinical trials for Multiple myeloma
·Clear filters·↓ Download CSVA Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
A Dietary Study for People With Multiple Myeloma
A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib
Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia
Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
Precision Medicine Study
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
Sequential Therapy in Multiple Myeloma Guided by MRD Assessments
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
The Ambient Light Multiple Myeloma Study
A Study of Daratumumab
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
About research studies in New York
New York has approximately 3,501 recruiting research studies across a wide range of therapeutic areas. New York is home to leading academic medical centers such as Memorial Sloan Kettering, Weill Cornell Medicine, Mount Sinai, NYU Langone, and Columbia University Irving Medical Center. These institutions anchor a research ecosystem that covers oncology, cardiology, neurology, and rare disease.
Top Research Study Locations in New York
Researchers run research studies in New York, NY at 25 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| Memorial Sloan Kettering Cancer Center | Breast Cancer, Prostate Cancer, Endometrial Cancer | 481 |
| NYU Langone Health | Lung Cancer, Prostate Cancer, Cardiovascular Diseases | 309 |
| Icahn School of Medicine at Mount Sinai | Myelofibrosis, Prostate Cancer, Advanced Solid Tumor | 263 |
| Columbia University Irving Medical Center | Obesity, Insulin Resistance, Prostate Cancer | 187 |
| Memorial Sloan Kettering Cancer Center (All Protocol Activities) | Breast Cancer, Multiple Myeloma, Metastatic Breast Cancer | 153 |
| Weill Cornell Medicine | Heart Failure, Depression, Prostate Cancer | 141 |
| Columbia University Medical Center | Breast Cancer, Advanced Solid Tumor, Coronary Artery Disease | 135 |
| Mount Sinai Hospital | Acute Myeloid Leukemia, Heart Failure, Anatomic Stage IV Breast Cancer AJCC v8 | 132 |
| Columbia University | Amyotrophic Lateral Sclerosis, Colorectal Cancer, Multiple Myeloma | 113 |
| Hospital for Special Surgery | Opioid Use, Rheumatoid Arthritis, Systemic Lupus Erythematosus | 69 |
| Laura and Isaac Perlmutter Cancer Center at NYU Langone | Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Malignant Solid Neoplasm, Stage IV Renal Cell Cancer AJCC v8 | 64 |
| NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center | Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Acute Myeloid Leukemia | 61 |
| Lenox Hill Hospital | Atrial Fibrillation, Anatomic Stage II Breast Cancer AJCC v8, Head and Neck Squamous Cell Carcinoma | 55 |
| Weill Cornell Medical College | ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome | 49 |
| Mount Sinai | Ovarian Cancer, AML, Advanced Solid Tumors | 44 |
| Mount Sinai West | Breast Cancer, Intracerebral Hemorrhage, Anatomic Stage II Breast Cancer AJCC v8 | 43 |
| Memorial Sloan Kettering Cancer Center (All Protocol Activites) | Breast Cancer, Prostate Cancer, Adult Cancer Patients | 38 |
| NYP/Weill Cornell Medical Center | B Acute Lymphoblastic Leukemia, Malignant Solid Neoplasm, Anatomic Stage IV Breast Cancer AJCC v8 | 35 |
| New York University | Inflammatory Bowel Disease (IBD), Adenine Phosphoribosyltransferase Deficiency, Arrhythmogenic Right Ventricular Cardiomyopathy | 33 |
| Memorial Sloan-Kettering Cancer Center | Advanced Solid Tumor, Advanced Solid Tumors, Breast Cancer | 27 |
| Mount Sinai Chelsea | Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Cancer | 24 |
| Manhattan Eye Ear and Throat Hospital | Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8 | 22 |
| NYU Langone | Gout, Acute Gastrointestinal Bleeding, Acute Gout Flare | 21 |
| Montefiore Medical Center | Mitral Regurgitation, Coronary Artery Disease, AML, Adult | 20 |
| NYU Langone Medical Center | Mesothelioma, NSCLC, Non Small Cell Lung Cancer | 20 |
Active & Upcoming Studies in New York (2026)
Recruiting trials in New York grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (1,213 active studies)
- Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC) · Phase 2 · Columbia University
- Veteran Peer Navigators to Promote Shared Decision Making for PSA Screening · VA Office of Research and Development
Neurology & pain (207 active studies)
- Neuronavigation-guided FUS-induced BBB Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau · Phase 1 · Columbia University
- Opioid Dispenser for Microdiscectomy/Laminectomy · Hospital for Special Surgery, New York
Cardiovascular (194 active studies)
Mental health & behavior (105 active studies)
- Permanent Supportive Housing Overdose Prevention+ Study · NYU Langone Health
- Technology dRiven Enhancement to Engage & Connect · Weill Medical College of Cornell University
Diabetes & metabolic (102 active studies)
- South Asians With Type 2 Diabetes at Risk for Depression · NYU Langone Health
- Human Models of Selective Insulin Resistance: Pancreatic Clamp · Phase 1 · Columbia University
HIV / STI (48 active studies)
Pediatric (34 active studies)
Vaccines (22 active studies)
- SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction · Phase 2 · Icahn School of Medicine at Mount Sinai
- Harnessing Optimism and Perseverance in the Face of Long COVID-Español · Icahn School of Medicine at Mount Sinai
Eye & vision (18 active studies)
- Know Your Pressures NYC · Columbia University
- Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions) · Phase 1 · Life Biosciences Inc.
Common conditions studied in New York
- Breast Cancer (93 active studies). Breast cancer trials evaluate new hormone therapies, targeted drugs, and immunotherapy combinations aimed at improving survival and reducing recurrence.
- Prostate Cancer (73 active studies). Prostate cancer studies test next-generation hormone therapies, PARP inhibitors, and radioligand treatments for both localized and advanced disease.
- Multiple Myeloma (51 active studies). Recruiting Multiple Myeloma studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Advanced Solid Tumor (42 active studies). Recruiting Advanced Solid Tumor studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Ovarian Cancer (42 active studies). Ovarian cancer research examines PARP inhibitors, maintenance therapies, and antibody-drug conjugates for recurrent and platinum-resistant disease.
- Colorectal Cancer (39 active studies). Colorectal cancer trials explore novel chemotherapy combinations, targeted agents, and immunotherapy for microsatellite-instability-high tumors.
Leading research sponsors in New York
- Memorial Sloan Kettering Cancer Center
- NYU Langone Health
- Columbia University
- Icahn School of Medicine at Mount Sinai
- Weill Medical College of Cornell University
Local regulations and guidelines
Clinical trials in New York are governed by U.S. Food and Drug Administration (FDA) regulations, Office for Human Research Protections (OHRP) standards, and federal HIPAA privacy rules. Every study is reviewed by an Institutional Review Board (IRB) to protect participant safety and ensure informed consent. Trials conducted in New York must also comply with the NY SHIELD Act's data-protection requirements and additional oversight from the New York State Department of Health.
Compensation & what to expect
- How payment typically works
- Compensation is most often provided through reloadable electronic study cards or direct deposit, paid out per completed visit rather than as a lump sum. Amounts vary by the time required, the number of visits, and the study's complexity — overnight stays and inpatient pharmacology studies generally pay more than short outpatient surveys. The exact amount is disclosed in writing during informed consent before any visit.
- Healthy volunteers
- Healthy participants aged 18 and older can earn compensation by joining vaccine, pharmacology, and biomarker studies in New York. These trials check how a new drug or vaccine behaves in healthy bodies before later-phase testing. Many sites maintain a healthy-volunteer registry so you hear about new opportunities first.
- What's included beyond payment
- Most trials cover study-related medical care at no cost — physical exams, lab work, imaging, the investigational treatment itself, and follow-up visits with the research team. Insurance is not required to participate. Free check-ups and access to specialists are common reasons participants return for additional studies.
- Travel and time
- Many sponsors reimburse travel, parking, mileage, and lost wages for visit days. Long-running studies and trials that require frequent visits often raise stipends accordingly. Ask the study coordinator for the visit schedule and reimbursement policy before you commit.
- Asking about compensation
- Compensation is set per protocol and per site, so figures are not published in trial registries. The fastest way to confirm payment for a specific study is to contact the recruiting site listed on the study record. Coordinators are accustomed to this question and will quote the per-visit and total amounts up front.
How to find a clinical trial in New York
Hipa.ai aggregates every recruiting study in New York from ClinicalTrials.gov and refreshes the list daily. Use the filters above to narrow by condition, facility, age, phase, or healthy-volunteer eligibility, then click any study title to view full details — eligibility criteria, intervention, location, and sponsor contact information. To enroll, reach out to the central study contact listed on the study detail page; the research coordinator will walk you through the screening process.
Frequently asked questions
How many paid clinical trials are currently recruiting in New York?
There are approximately 3,501 recruiting clinical trials in New York, New York listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in New York pay participants?
Most recruiting trials in New York compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in New York?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in New York?
The most common conditions under active study in New York include Breast Cancer (93), Prostate Cancer (73), Multiple Myeloma (51), Advanced Solid Tumor (42), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in New York?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in New York on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in New York?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in New York?
Recruiting research sites in New York include Memorial Sloan Kettering Cancer Center, NYU Langone Health, Icahn School of Medicine at Mount Sinai, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in New York right now?
The largest active categories in New York are Cancer & tumors (1,213), Neurology & pain (207), Cardiovascular (194). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.